ClinicalTrials.gg
Not yet recruitingNCT07711899non applicableUpdated Jul 20, 2026

Plasma Taurine in Older Women With Obesity: Impact of Metabolic Phenotype and Combined Exercise

An interventional study of Physical Training of 16 weeks in Obesity (BMI>30), Metabolically Healthy Obesity and Metabolically Unhealty Obese, sponsored by University of Sao Paulo. Not yet recruiting. Open to female participants aged 60 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-20.

Primary conditionObesity, Metabolically BenignRegistry: ObesityReclassifiedWhy we changed it
Registry
Obesity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity, Metabolically Benign
Why
  1. The study's listed conditions name Obesity, Metabolically Benign, a narrower term within Obesity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Sao Paulo · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
60 Years to 75 Years
Sex
Female
01

Study summary

Population aging has been accompanied by a rise in obesity and other chronic diseases, increasing cardiovascular risk particularly among women, who exhibit a higher prevalence in older age groups compared to men. Aging and obesity share pathophysiological mechanisms, such as chronic inflammation and oxidative stress. However, distinct obesity phenotypes exist, such as metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO). Consequently, therapeutic interventions involving nutritional strategies and physical training are highly relevant, especially for older women. Taurine, a sulfur-containing amino acid, plays a role in modulating oxidative stress, inflammation, osmoregulation, and mitochondrial function. Rationale: Plasma taurine concentrations are lower in women with obesity compared to healthy individuals. However, studies investigating these concentrations across different phenotypes-particularly in older women, a group susceptible to functional and metabolic changes-remain limited. Understanding these variations could clarify taurine's role in the pathophysiology of obesity and aging and inform personalized therapeutic strategies. Combined physical training stands out as an effective strategy for modulating inflammatory, oxidative, and metabolic pathways, in addition to improving psychosocial aspects. Given that taurine levels can be influenced by these pathways, investigating the taurine response to physical training across different metabolic phenotypes may contribute to developing low-cost interventions aimed at improving the quality of life for older women with obesity.

Read the detailed description

This study aims to investigate differences in plasma taurine concentrations between older women with MHO and MUO, and to evaluate the response of taurine-as well as metabolic, inflammatory, oxidative, and cellular markers-to a 16-week combined physical training intervention. The study will involve 36 older women with obesity, classified as having either MHO or MUO. In Stage 1, nutritional and anthropometric assessments will be conducted, along with the collection of biological samples for biochemical and molecular analyses. In Stage 2, participants will undergo a combined physical exercise intervention for 16 weeks; nutritional, anthropometric, physical performance, and functional assessments will be performed, as well as the collection of biological samples for pre- and post-intervention biochemical and molecular analyses. Stage 3 will consist of integrated data analysis to identify variables predicting plasma taurine concentrations at baseline and post-intervention. Data analysis method: Data will be analyzed using Student's t-tests or Mann-Whitney tests (Stage 1), ANOVA or Kruskal-Wallis tests (Stage 2), Pearson or Spearman correlations (Stages 1 and 2), and linear regression models (Stage 3), using SPSS software (α=5%). Expected results: It is expected that older women with OMS will exhibit higher baseline taurine concentrations and that combined physical training will increase these concentrations in both groups-with a more pronounced effect in the OMS phenotype-in addition to promoting cardiometabolic, functional, inflammatory, oxidative, and psychosocial benefits.

02

Conditions studied

  • Obesity (BMI>30)
  • Metabolically Healthy Obesity
  • Metabolically Unhealty Obese

Browse trials for

Keywords

  • Taurine
  • Metabolically unhealthy obesity.
  • Metabolically healthy obesity.
  • Physical training
  • Aging
03

In context

Obesity, Metabolically Benign Reclassified

27 studies on the registry are indexed under Obesity, Metabolically Benign; 8 are open to participants now.

This study's planned enrollment of 36 is below the median of 60 across 17 interventional studies indexed under Obesity, Metabolically Benign.

Browse Obesity, Metabolically Benign studies →

Lead sponsor

University of Sao Paulo is the lead sponsor of 1,036 studies on the registry; 96 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Obesity, Metabolically Benign, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
60 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 60 to 75 years.
  • Residents of the city or region of Ribeirão Preto, São Paulo, Brazil.
  • Physically inactive for at least 3 months.
  • (BMI) ≥ 30 kg/m² (PAHO, 2002).
  • Body fat percentage ≥ 35%, according to obesity diagnostic criteria (Batsis et al., 2016; Rubino et al., 2025).

Classified into one of two obesity phenotypes based on Zembic et al. (2021):

Metabolically Healthy Obesity (MHO/OMS): all of the following criteria must be met:

  • Systolic blood pressure (SBP) \< 130 mmHg;
  • Waist-to-hip ratio \< 0.95;
  • Fasting blood glucose \< 126 mg/dL.

Metabolically Unhealthy Obesity (MUO/OMNS): meets two or fewer of the above criteria.

Exclusion criteria

Exclusion Criteria

Clinical conditions

  • to physical exercise.
  • Current or previous diagnosis of:

    • Neoplasms;
    • diseases;
    • Hepatic diseases;
    • Coronary diseases;
    • Renal diseases;
    • Neurodegenerative diseases;
    • Infectious diseases.

Previous or ongoing treatments

  • Use of medication for thyroid disorders.
  • Participation in exercise training programs, nutritional counseling, or weight loss treatment within the 3 months preceding the intervention.

Lifestyle habits

  • Current smoking.
  • Alcohol consumption.

For MHO Group:

  • Medication use

    • Hypoglycemic agents
    • Insulin (Bell, Kivimäki, \& Hamer, 2014).
  • Protocol adherence *Attendance at less than 80% of the training sessions (De Carvalho et al., 2021).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Other
    Metabolically Healthy Obesity (MHO)

    Women with metabolically healthy obesity who participate in regular exercise. Participants will undergo the study assessments for comparison with the other obesity phenotype.

    Behavioral: Physical Training of 16 weeks

  • Other
    Metabolically Unhealthy Obesity (MUO)

    Women with metabolically unhealthy obesity who participate in regular exercise. Participants will undergo the study assessments for comparison with the other obesity phenotype.

    Behavioral: Physical Training of 16 weeks

Interventions

  • BehavioralPhysical Training of 16 weeks

    Combined physical Training during 16 weeks

06

What researchers measure

Primary outcomes

  1. Plasma taurine concentrations (µmol/L).

    It will be analyzed by high-performance liquid chromatography.

    Time frame: 16 weeks

Secondary outcomes

  1. Systolic and diastolic blood pressure (mmHg)

    Using sphygmomanometer

    Time frame: 16 weeks

  2. Waist and hip circumferences (cm)

    non-stretch anthropometric tape

    Time frame: 16 weeks

  3. Appendicular lean soft tissue (kg).

    Using Dual-energy X-ray Absorptiometry (DXA), often referred to as iDXA, is a low-dose X-ray technology that measures bone mineral density (BMD) and body composition

    Time frame: 16 Weeks

  4. Total and regional body fat percentage (%)

    Dual-energy X-ray Absorptiometry

    Time frame: 16 weeks

  5. Visceral fat (kg)

    Dual-energy X-ray Absorptiometry

    Time frame: 16 weeks

  6. Body mass (kg)

    Dual-energy X-ray Absorptiometry

    Time frame: 16 weeks

  7. Body mass index, BMI (kg/m²).

    Using body mass and height measurements

    Time frame: 16 weeks

  8. Inflammatory and antiinflamatory profile

    Changes in serum levels of cytokines will be evaluated with MILLIPLEX® Kit. Pro- inflammatory citokines: IL-1β, MCP-1,TNF-α, IL-6, IL-13 (pg/mL), leptina e PCR-us (mg/dL), IL-10 (pg/mL) e adiponectina (mg/dL).

    Time frame: 16 weeks

  9. Food Intake

    A food record of three non-consecutive days: two days of the week and one day in the weekend. This evaluation will last 16 weeks. Will be evaluated with Dietwin® software (São Paulo, Brazil): The macronutrients, micronutrients and fiber in quilocalories and percentage (%)

    Time frame: 16 weeks

  10. Aerobic performance - VO2

    Physical tests performed pre and post- intervention to assess aerobic physical fitness by incremental test in cycle ergometer. The test aim to evaluate VO2peak in ml.kg-1.min-1.

    Time frame: 16 weeks

  11. Aerobic performance - LacAnTh

    Physical tests performed pre and post- intervention to assess aerobic physical fitness by incremental test in cycle ergometer. The test aim to evaluate: Anaerobic threshold (AT) using lactate concentration \[lac-\].

    Time frame: 16 weeks

  12. Aerobic performance - IAnTh

    Physical tests performed pre and post- intervention to assess aerobic physical fitness by incremental test in cycle ergometer. The test aim to evaluate: Anaerobic threshold (AT) using intensity in Watts (W).

    Time frame: 16 weeks

  13. Aerobic performance - HRAnTh

    Physical tests performed pre and post- intervention to assess aerobic physical fitness by incremental test in cycle ergometer. The test aim to evaluate: Anaerobic threshold (AT) using heart rate (HR).

    Time frame: 16 weeks

  14. Food intake - frequency

    Application of Food Frequency Questionnaire, QFA-NOVA for each food group (g/group).

    Time frame: 16 weeks

  15. Strength test - leg press

    Strength test - leg press - maximum repetitions pre and post intervention

    Time frame: 16 weeks

  16. Strength test - bench press

    Strength test using bench press, pre and post intervention

    Time frame: 16 weeks

  17. Funtional capacity: chair sit-to-stand

    Funtional capacity evaluation pre and post intervention

    Time frame: 16 weeks

  18. handgrip strength

    handgrip strength using manual dinamometer

    Time frame: 16 weeks

  19. funtional capacity: elbow flexion and extension

    funtional capacity: elbow flexion and extension using a dumpbell

    Time frame: 16 weeks

  20. Funtional capacity: 6-minute walk test

    6-minute walk test using an 30-meter course with markings every 3 meters.

    Time frame: 16 weeks

  21. Glycemic profile

    Quantified by Total Liquiform Cholesterol Kit, HDL Cholesterol Kit and Liquiform Triglycerides Kit, from Labtest diagnóstica®, using an enzymatic system and absorbance spectrophotometer: Changes in blood glucose (mg/dL).

    Time frame: 16 weeks

  22. Lipid profile - Total cholesterol

    Quantified by Total Liquiform Cholesterol Kit, HDL Cholesterol Kit and Liquiform Triglycerides Kit, from Labtest diagnóstica®, using an enzymatic system and absorbance spectrophotometer: Changes in total cholesterol (mg/dL).

    Time frame: 16 weeks

  23. Lipid profile: HDL-cholesterol and LDL-cholesterol (mg/dL).

    Quantified by Total Liquiform Cholesterol Kit, HDL Cholesterol Kit and Liquiform Triglycerides Kit, from Labtest diagnóstica®, using an enzymatic system and absorbance spectrophotometer: Changes in HDL-cholesterol and LDL-cholesterol (mg/dL).

    Time frame: 16 weeks

  24. Lipid profile: triglycerides (mg/dL).

    Quantified by Total Liquiform Cholesterol Kit, HDL Cholesterol Kit and Liquiform Triglycerides Kit, from Labtest diagnóstica®, using an enzymatic system and absorbance spectrophotometer: Changes in triglycerides (mg/dL).

    Time frame: 16 weeks

  25. Glycemic profile - C-peptide

    C-peptide pre and post intervention using Chemiluminescence (CLIA - Chemiluminescent Immunoassay)

    Time frame: 16 weeks

  26. Expression of inflammatory and anti-inflammatory genes in peripheral blood mononuclear cells (PBMCs)

    Using RT-qPCR pre and post-intervention.

    Time frame: 16 weeks

  27. Expression of genes related to telomere length: TRF1, TRF2, RAP1, TPP1, POT1, TIN2, and hTERT.

    Using RT-qPCR pre and post intervention

    Time frame: 16 weeks

  28. Micronutrients (mg/dL)

    Blood Zinc, selenium, and magnesium (mg/dL) using spectrophotometry pre and post intervention

    Time frame: 16 weeks

  29. Antioxidant enzymes - Superoxide dismutase

    Superoxide Dismutase (SOD) Assay Kit Pre and post intervention (U/mg)

    Time frame: 16 weeks

  30. Antioxidants enzymes - Catalase (CAT)

    Catalase Assay Kit Pre and post intervention (U/mg)

    Time frame: 16 weeks

  31. Antioxidants enzymes: Glutationa-peroxidase GPx (U/mg)

    Glutathione Peroxidase Assay Kit Pre and post intervention

    Time frame: 16 weeks

  32. Oxidative stress markers - Malondialdehyde (nmol/mL).

    TBARS (Thiobarbituric Acid Reactive Substances) assay pre and post intervention

    Time frame: 16 weeks

  33. Relative telomere length

    The assay will be based on quantifying the ratio between the amplification of telomeric sequences (T) and a single-copy gene (S), enabling the estimation of relative telomere length in the biological samples.

    Time frame: 16 weeks

  34. Nitrogen balance

    Urinary nitrogen excretion (g) will be determined using the Labtest Diagnóstica kit (UREA CE), estimating urinary nitrogen excretion based on urea levels. Daily protein intake will also be used, pre and post intervention

    Time frame: 16 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 17, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Mar 1, 2030
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07711899
Responsible party
Ellen Cristini de Freitas (Responsible Investigator, University of Sao Paulo) — Principal investigator
First posted
Jul 17, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Mar 1, 2030 (estimated)
Last update
Jul 20, 2026

Study contacts

Ellen Cristini de Freitas, Dr
Contact
ellenfreitas@usp.br
+551633150345

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion